{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:02:21Z","timestamp":1790143341095,"version":"4.0.1"},"reference-count":338,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd016017","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:16:04Z","timestamp":1761783364000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Liraglutide for adults living with obesity"],"prefix":"10.1002","volume":"2025","author":[{"given":"Nicol\u00e1s","family":"Meza","sequence":"additional","affiliation":[{"name":"Cochrane Evidence Synthesis Unit Iberoam\u00e9rica, Interdisciplinary Centre for Health Studies (CIESAL); Universidad de Valpara\u00edso; Vi\u00f1a del Mar Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Bracchiglione","sequence":"additional","affiliation":[{"name":"Cochrane Evidence Synthesis Unit Iberoam\u00e9rica, Interdisciplinary Centre for Health Studies (CIESAL); Universidad de Valpara\u00edso; Vi\u00f1a del Mar Chile"},{"name":"CIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP); Instituto de Salud Carlos III; Madrid Spain"},{"name":"Iberoamerican Cochrane Centre; Institut de Recerca Sant Pau (IR SANT PAU); Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila Micaela","family":"Escobar Liquitay","sequence":"additional","affiliation":[{"name":"Cochrane Evidence Synthesis Unit Iberoam\u00e9rica, Research Department; Universidad del Hospital Italiano de Buenos Aires; Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Madrid","sequence":"additional","affiliation":[{"name":"Cochrane Evidence Synthesis Unit Iberoam\u00e9rica, Interdisciplinary Centre for Health Studies (CIESAL); Universidad de Valpara\u00edso; Vi\u00f1a del Mar Chile"},{"name":"Iberoamerican Cochrane Centre, Institut de Recerca Sant Pau (IR SANT PAU); Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia B","family":"Varela","sequence":"additional","affiliation":[{"name":"Cochrane Evidence Synthesis Unit Iberoam\u00e9rica, Research Department; Universidad del Hospital Italiano de Buenos Aires; Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Guo","sequence":"additional","affiliation":[{"name":"Cochrane Evidence Synthesis Unit Germany\/UK - D\u00fcsseldorf Subunit, Institute of General Practice, Centre for Health and Society, Medical Faculty; Heinrich Heine University D\u00fcsseldorf; D\u00fcsseldorf Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Urr\u00fatia","sequence":"additional","affiliation":[{"name":"CIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP); Instituto de Salud Carlos III; Madrid Spain"},{"name":"Iberoamerican Cochrane Centre; Institut de Recerca Sant Pau (IR SANT PAU); Barcelona Spain"},{"name":"Universitat Aut\u00f2noma de Barcelona; Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selcuk","family":"Er","sequence":"additional","affiliation":[{"name":"Cochrane Evidence Synthesis Unit Germany\/UK - D\u00fcsseldorf Subunit, Institute of General Practice, Centre for Health and Society, Medical Faculty; Heinrich Heine University D\u00fcsseldorf; D\u00fcsseldorf Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Tiller","sequence":"additional","affiliation":[{"name":"Cochrane Evidence Synthesis Unit Germany\/UK - D\u00fcsseldorf Subunit, Institute of General Practice, Centre for Health and Society, Medical Faculty; Heinrich Heine University D\u00fcsseldorf; D\u00fcsseldorf Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamyar","family":"Shokraee","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Medizinische Fakult\u00e4t; Ludwig-Maximilians-Universit\u00e4t; Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Alvarez Busco","sequence":"additional","affiliation":[{"name":"School of Medicine; Universidad de Valpara\u00edso; Vi\u00f1a del Mar Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Sol\u00e0","sequence":"additional","affiliation":[{"name":"CIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP); Instituto de Salud Carlos III; Madrid Spain"},{"name":"Iberoamerican Cochrane Centre; Institut de Recerca Sant Pau (IR SANT PAU); Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda","family":"Ocara Vargas","sequence":"additional","affiliation":[{"name":"School of Medicine; Universidad de Valpara\u00edso; Vi\u00f1a del Mar Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Novik A","sequence":"additional","affiliation":[{"name":"School of Medicine; Universidad de Valpara\u00edso; Vi\u00f1a del Mar Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Poloni","sequence":"additional","affiliation":[{"name":"School of Medicine; Universidad de Valpara\u00edso; Vi\u00f1a del Mar Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan VA","family":"Franco","sequence":"additional","affiliation":[{"name":"Cochrane Evidence Synthesis Unit Germany\/UK - D\u00fcsseldorf Subunit, Institute of General Practice, Centre for Health and Society, Medical Faculty; Heinrich Heine University D\u00fcsseldorf; D\u00fcsseldorf Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"10.1002\/14651858.CD016017-BIB0001|cit1","unstructured":"World Health Organization Obesity and overweight www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight"},{"issue":"1","key":"10.1002\/14651858.CD016017-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"19778","DOI":"10.1038\/s41598-020-75213-3","article-title":"The ongoing nutrition transition thwarts long-term targets for food security, public health and environmental protection","volume":"10","author":"Bodirsky","year":"2020","journal-title":"Scientific Reports"},{"issue":"9","key":"10.1002\/14651858.CD016017-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"e009773","DOI":"10.1136\/bmjgh-2022-009773","article-title":"Economic impacts of overweight and obesity: current and future estimates for 161 countries","volume":"7","author":"Okunogbe","year":"2022","journal-title":"BMJ Global Health"},{"issue":"10258","key":"10.1002\/14651858.CD016017-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","article-title":"Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"GBD 2019 Risk Factors Collaborators","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD016017-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet. Diabetes & Endocrinology"},{"issue":"5","key":"10.1002\/14651858.CD016017-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41574-019-0176-8","article-title":"Obesity: global epidemiology and pathogenesis","volume":"15","author":"Bl\u00fcher","year":"2019","journal-title":"Nature Reviews. Endocrinology"},{"issue":"1","key":"10.1002\/14651858.CD016017-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12916-019-1474-7","article-title":"Lifestyle factors and risk of multimorbidity of cancer and cardiometabolic diseases: a multinational cohort study","volume":"18","author":"Freisling","year":"2020","journal-title":"BMC Medicine"},{"issue":"5","key":"10.1002\/14651858.CD016017-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"e1002571","DOI":"10.1371\/journal.pmed.1002571","article-title":"Clinical, socioeconomic, and behavioural factors at age 50 years and risk of cardiometabolic multimorbidity and mortality: a cohort study","volume":"15","author":"Singh-Manoux","year":"2018","journal-title":"PLoS Medicine"},{"issue":"2019","key":"10.1002\/14651858.CD016017-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.metabol.2018.10.010","article-title":"Pharmacotherapy of obesity: available medications and drugs under investigation","volume":"92","author":"Pilitsi","year":"2019","journal-title":"Metabolism: Clinical and Experimental"},{"issue":"2","key":"10.1002\/14651858.CD016017-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2337\/diacare.29.02.06.dc05-1636","article-title":"The importance of waist circumference in the definition of metabolic syndrome: prospective analyses of mortality in men","volume":"29","author":"Katzmarzyk","year":"2006","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD016017-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s10557-022-07360-w","article-title":"Effects of glucagon-like peptide-1 receptor agonist (GLP-1RA) on cardiac structure and function: a systematic review and meta-analysis of randomized-controlled trials","volume":"38","author":"Wong","year":"2024","journal-title":"Cardiovascular Drugs and Therapy \/ Sponsored by the International Society of Cardiovascular Pharmacotherapy"},{"issue":"4","key":"10.1002\/14651858.CD016017-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3390\/ijerph14040435","article-title":"Economic burden of obesity: a systematic literature review","volume":"14","author":"Tremmel","year":"2017","journal-title":"International Journal of Environmental Research and Public Health"},{"issue":"1","key":"10.1002\/14651858.CD016017-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jhealeco.2011.10.003","article-title":"The medical care costs of obesity: an instrumental variables approach","volume":"31","author":"Cawley","year":"2012","journal-title":"Journal of Health Economics"},{"issue":"5","key":"10.1002\/14651858.CD016017-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"w822","DOI":"10.1377\/hlthaff.28.5.w822","article-title":"Annual medical spending attributable to obesity: payer-and service-specific estimates","volume":"28","author":"Finkelstein","year":"2009","journal-title":"Health Affairs (Project Hope) (Millwood)"},{"issue":"1","key":"10.1002\/14651858.CD016017-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"3","key":"10.1002\/14651858.CD016017-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.2337\/ds16-0026","article-title":"Glucagon-like peptide 1 receptor agonists for type 2 diabetes","volume":"30","author":"Hinnen","year":"2017","journal-title":"Diabetes Spectrum"},{"issue":"2","key":"10.1002\/14651858.CD016017-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.7326\/ANNALS-24-01590","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes: a systematic review of randomized controlled trials","volume":"178","author":"Moiz","year":"2025","journal-title":"Annals of Internal Medicine"},{"issue":"384","key":"10.1002\/14651858.CD016017-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"e076410","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"1","author":"Yao","year":"2024","journal-title":"BMJ"},{"issue":"7","key":"10.1002\/14651858.CD016017-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes. The SCALE Diabetes Randomized Clinical Trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD016017-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"82\u20133","DOI":"10.1056\/NEJMe1506236","article-title":"Another agent for obesity - will this time be different?","volume":"373","author":"Siraj","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"10455","key":"10.1002\/14651858.CD016017-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/S0140-6736(24)01356-4","article-title":"International coverage of GLP-1 receptor agonists: a review and ethical analysis of discordant approaches","volume":"404","author":"Dellgren","year":"2024","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD016017-BIB0022|cit22","doi-asserted-by":"crossref","unstructured":"Anderer S FDA approves generic liraglutide to address GLP-1 drug shortage JAMA 2025 333 9 746 10.1001\/jama.2024.28813","DOI":"10.1001\/jama.2024.28813"},{"issue":"7","key":"10.1002\/14651858.CD016017-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jama.2024.25872","article-title":"Obesity and glucagon-like peptide-1 receptor agonists","volume":"333","author":"Celletti","year":"2025","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD016017-BIB0024|cit24","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012204.pub2","article-title":"Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus","author":"Hemmingsen","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD016017-BIB0025|cit25","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011798.pub2","article-title":"Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease","author":"Lo","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD016017-BIB0026|cit26","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006423.pub2","article-title":"Glucagon-like peptide analogues for type 2 diabetes mellitus","author":"Shyangdan","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD016017-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2337\/dc24-1678","article-title":"Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials","volume":"48","author":"Wong","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD016017-BIB0028|cit28","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Standards for the conduct of new Cochrane Intervention Reviews. In: Higgins JP, Lasserson T, Thomas J, Flemyng E, Churchill R. Methodological Expectations of Cochrane Intervention Reviews Cochrane: London"},{"issue":"71","key":"10.1002\/14651858.CD016017-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"9","key":"10.1002\/14651858.CD016017-BIB0030|cit30","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015092","article-title":"Glucagon-like peptide-1 analogues for overweight or obese adults","author":"Madrid","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD016017-BIB0031|cit31","unstructured":"Madrid E Franco J Meza N Bracchiglione J Ocara M Escobar-Liquitay C Glucagon-like peptide-1 (GLP-1) analogues for adult people with obesity: protocol for asystematic review with meta-analysis Available from https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420250654193"},{"key":"10.1002\/14651858.CD016017-BIB0032|cit32","unstructured":"US Food & Drug Administration - Assistance with FDA regulation www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/209637Orig1s000TOC.cfm"},{"issue":"5","key":"10.1002\/14651858.CD016017-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Annals of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD016017-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000376585","article-title":"The WHO-5 Well-Being Index: a systematic review of the literature","volume":"84","author":"Topp","year":"2015","journal-title":"Psychotherapy and Psychosomatics"},{"issue":"6","key":"10.1002\/14651858.CD016017-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Sherbourne","year":"1992","journal-title":"Medical Care"},{"issue":"2","key":"10.1002\/14651858.CD016017-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/oxfordjournals.pubmed.a024606","article-title":"A shorter form health survey: can the SF-12 replicate results from the SF-36 in longitudinal studies?","volume":"19","author":"Jenkinson","year":"1997","journal-title":"Journal of Public Health"},{"issue":"2","key":"10.1002\/14651858.CD016017-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"e12961","DOI":"10.1111\/obr.12961","article-title":"Core outcome set for behavioural weight management interventions for adults with overweight and obesity: standardised reporting of lifestyle weight management interventions to aid evaluation (STAR-LITE)","volume":"21","author":"Mackenzie","year":"2020","journal-title":"Obesity Reviews"},{"key":"10.1002\/14651858.CD016017-BIB0038|cit38","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Technical Supplement to Chapter 4: Searching for and selecting studies (last updated September 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016017-BIB0039|cit39","unstructured":"Covidence Veritas Health Innovation 2022"},{"key":"10.1002\/14651858.CD016017-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"g1687","DOI":"10.1136\/bmj.g1687","article-title":"Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide","volume":"348","author":"Hoffmann","year":"2014","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016017-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"j2998","DOI":"10.1136\/bmj.j2998","article-title":"Enhancing the usability of systematic reviews by improving the consideration and description of interventions","volume":"358","author":"Hoffmann","year":"2017","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016017-BIB0042|cit42","unstructured":"Li T Higgins JP Deeks JJ Chapter 5: Collecting data (last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-05"},{"key":"10.1002\/14651858.CD016017-BIB0043|cit43","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016017-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016017-BIB0045|cit45","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect (last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-06"},{"key":"10.1002\/14651858.CD016017-BIB0046|cit46","unstructured":"Page MJ Higgins JP Sterne JA Chapter 13: Assessing risk of bias due to missing evidence in a meta-analysis (last updated August 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-13"},{"key":"10.1002\/14651858.CD016017-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016017-BIB0048|cit48","unstructured":"Deeks JJ Higgins JP Altman DG McKenzie JE Veroniki AA Chapter 10: Analysing data and undertaking meta-analyses (last updated November 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-10#section-10-1"},{"key":"10.1002\/14651858.CD016017-BIB0049|cit49","unstructured":"McKenzie JE Brennan SE Chapter 12: Synthesizing and presenting findings using other methods (last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016017-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"7382","key":"10.1002\/14651858.CD016017-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Interaction revisited: the difference between two estimates","volume":"326","author":"Altman","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016017-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jclinepi.2022.07.014","article-title":"GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach","volume":"150","author":"Zeng","year":"2022","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD016017-BIB0053|cit53","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-25-00548","article-title":"GRADE certainty ratings: thresholds rather than categories of contextualization (GRADE Guidance 41)","volume":"2025","author":"Hultcrantz","year":"2025","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD016017-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2023.03.003","article-title":"GRADE guidance 36: updates to GRADE's approach to addressing inconsistency","volume":"158","author":"Guyatt","year":"2023","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD016017-BIB0055|cit55","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence (last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-14"},{"key":"10.1002\/14651858.CD016017-BIB0056|cit56","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2025"},{"key":"10.1002\/14651858.CD016017-BIB0057|cit57","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2024"},{"key":"10.1002\/14651858.CD016017-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jclinepi.2015.12.006","article-title":"Improving GRADE evidence tables part 3: detailed guidance for explanatory footnotes supports creating and understanding GRADE certainty in the evidence judgments","volume":"74","author":"Santesso","year":"2016","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD016017-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","article-title":"GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions","volume":"119","author":"Santesso","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD016017-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"e12432","DOI":"10.1111\/cob.12432","article-title":"Efficacy and safety of glucagon-like peptide-1\/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: a randomized dose-ranging study","volume":"11","author":"Alba","year":"2021","journal-title":"Clinical Obesity"},{"key":"10.1002\/14651858.CD016017-BIB0061|cit61","unstructured":"A study to evaluate the safety and efficacy of JNJ-64565111 in non-diabetic severely obese subjects https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=EUCTR2017-003616-39-SE 2018"},{"key":"10.1002\/14651858.CD016017-BIB0062|cit62","unstructured":"A study to evaluate the safety and efficacy of JNJ-64565111 in non-diabetic severely obese participants https:\/\/clinicaltrials.gov\/study\/NCT03486392"},{"key":"10.1002\/14651858.CD016017-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2147\/COPD.S350133","article-title":"Respiratory effects of treatment with a glucagon-like peptide-1 receptor agonist in patients suffering from obesity and chronic obstructive pulmonary disease","volume":"17","author":"Altintas Dogan","year":"2022","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD016017-BIB0064|cit64","unstructured":"Effects of liraglutide in chronic obstructive pulmonary disease https:\/\/clinicaltrials.gov\/study\/NCT03466021"},{"issue":"9701","key":"10.1002\/14651858.CD016017-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD016017-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1038\/oby.2010.156","article-title":"Liraglutide once daily reduces the prevalence of prediabetes and metabolic syndrome in obese non-diabetic adults: a 2-year randomized trial","volume":"18 Suppl 2","author":"Niskanen","year":"2010","journal-title":"Obesity (Silver Spring, Md.)"},{"issue":"6","key":"10.1002\/14651858.CD016017-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/ijo.2011.158","article-title":"Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide","volume":"36","author":"Astrup","year":"2012","journal-title":"International Journal of Obesity"},{"key":"10.1002\/14651858.CD016017-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1467-789X.2011.00888.x","article-title":"Liraglutide in obese adults is effective and has acceptable tolerability over 2 years","volume":"12","author":"Astrup","year":"2011","journal-title":"Obesity Reviews"},{"key":"10.1002\/14651858.CD016017-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1753-0407.2011.00120.x","article-title":"Liraglutide once daily reduces the prevalence of prediabetes and metabolic syndrome in obese non-diabetic adults over two years","volume":"3 Suppl 1","author":"Finer","year":"2011","journal-title":"Journal of Diabetes"},{"key":"10.1002\/14651858.CD016017-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1467-789X.2011.00877.x","article-title":"Incidence and effects of nausea on weight loss and quality of life with the GLP-1 analogue liraglutide: a 52-week randomised trial","volume":"12","author":"Lean","year":"2011","journal-title":"Obesity Reviews"},{"key":"10.1002\/14651858.CD016017-BIB0071|cit71","first-page":"S153","article-title":"Sustained weight loss and acceptable tolerability with the GLP-1 analogue liraglutide in obese non-diabetic adults: a 2-year randomized trial","volume":"18 Suppl 2","author":"Lean","year":"2010","journal-title":"Obesity (Silver Spring, Md.)"},{"issue":"5","key":"10.1002\/14651858.CD016017-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/ijo.2013.149","article-title":"Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults","volume":"38","author":"Lean","year":"2014","journal-title":"International Journal of Obesity"},{"key":"10.1002\/14651858.CD016017-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"1064\u20136","DOI":"10.1007\/s00108-010-2694-2","article-title":"Therapie der Adipositas mit Liraglutid","volume":"51","author":"Scherbaum","year":"2010","journal-title":"Internist"},{"key":"10.1002\/14651858.CD016017-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1467-789X.2010.00763-4.x","article-title":"Tolerability and weight loss effects of liraglutide in obese adults: a 104-week randomised trial","volume":"11 Suppl 1","author":"Astrup","year":"2010","journal-title":"Obesity Reviews"},{"key":"10.1002\/14651858.CD016017-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1159\/000188329","article-title":"Additional measures to evaluate the effect of liraglutide 3.0 mg on weight loss in obese adults without diabetes: a randomised placebocontrolled trial","volume":"5 Suppl 1","author":"Finer","year":"2012","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD016017-BIB0076|cit76","unstructured":"The effect of liraglutide on body weight in obese subjects without diabetes https:\/\/clinicaltrials.gov\/study\/NCT00422058 2007"},{"key":"10.1002\/14651858.CD016017-BIB0077|cit77","unstructured":"Effect of liraglutide on body weight in obese subjects without diabetes A 20-week randomised, double-blind, placebo-controlled, six armed parallel group, multi-centre, multinational trial with an open label orlistat comparator arm Trial Phase:2b https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2006-004481-13\/SE 2006"},{"issue":"2","key":"10.1002\/14651858.CD016017-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.fertnstert.2022.04.027","article-title":"Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study","volume":"118","author":"Elkind-Hirsch","year":"2022","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD016017-BIB0079|cit79","unstructured":"Liraglutide 3mg (Saxenda) on weight, body composition, hormonal and metabolic parameters in obese women with PCOS (SAXAPCOS) https:\/\/clinicaltrials.gov\/study\/NCT03480022"},{"issue":"5","key":"10.1002\/14651858.CD016017-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/liv.14065","article-title":"Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease","volume":"39","author":"Khoo","year":"2019","journal-title":"Liver International"},{"key":"10.1002\/14651858.CD016017-BIB0081|cit81","unstructured":"Comparing effects of liraglutide and bariatric surgery on weight loss, liver function, body composition, insulin resistance, endothelial function and biomarkers of non-alcoholic steatohepatitis (NASH) in obese Asian adults (CGH-linash) https:\/\/clinicaltrials.gov\/study\/NCT02654665 2016"},{"key":"10.1002\/14651858.CD016017-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"238-9","DOI":"10.1159\/000489691","article-title":"Effects of lifestyle modification- versus liraglutide-induced weight loss and subsequent weight maintenance on hepatic steatosis and inflammation in obese adults with non-alcoholic fatty liver disease","volume":"11","author":"Khoo","year":"2018","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD016017-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"174-5","DOI":"10.1111\/jgh.13878","article-title":"A pilot randomized controlled trial (RCT) of 26 weeks of lifestyle modifications (LM) versus liraglutide (LG) in reducing severity of nonalcoholic steatohepatitis (NASH) in Asian adults","volume":"32","author":"Kumar","year":"2017","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD016017-BIB0084|cit84","first-page":"61","article-title":"Comparing effects of liraglutide-induced weight loss versus lifestyle modification on liver fat content and plasma acylcarnitine levels in obese adults with non-alcoholic fatty liver disease","volume":"12","author":"Khoo","year":"2019","journal-title":"Obesity Facts"},{"issue":"10317","key":"10.1002\/14651858.CD016017-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD016017-BIB0086|cit86","unstructured":"Research study investigating how well NNC0174-0833 works in people suffering from overweight or obesity https:\/\/clinicaltrials.gov\/study\/NCT03856047"},{"key":"10.1002\/14651858.CD016017-BIB0087|cit87","unstructured":"Research study investigating how well NNC0174-0833 works in people suffering from overweight or obesity https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2018-001945-14\/GB 2018"},{"issue":"2","key":"10.1002\/14651858.CD016017-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/ajcn\/nqaa328","article-title":"Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial","volume":"113","author":"Gudbergsen","year":"2021","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1002\/14651858.CD016017-BIB0089|cit89","unstructured":"Biomarkers in obese patients with knee osteoarthritis; weight maintenance (BIO-LOSEIT-II) https:\/\/clinicaltrials.gov\/study\/NCT02928614"},{"key":"10.1002\/14651858.CD016017-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"e024065","DOI":"10.1136\/bmjopen-2018-024065","article-title":"Effect of liraglutide on body weight and pain in patients with overweight and knee osteoarthritis: protocol for a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial","volume":"9","author":"Gudbergsen","year":"2019","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD016017-BIB0091|cit91","unstructured":"Changes in skin autoflouresence following weight loss and maintenance using liraglutide in knee osteoarthritis https:\/\/clinicaltrials.gov\/study\/NCT02910570"},{"key":"10.1002\/14651858.CD016017-BIB0092|cit92","unstructured":"Liraglutide 3 mg for knee osteoarthritis (LOSEIT) https:\/\/clinicaltrials.gov\/study\/NCT02905864"},{"key":"10.1002\/14651858.CD016017-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"S427-S429","DOI":"10.1016\/j.joca.2021.02.554","article-title":"Changes in physical activity during a one-year weight loss trial with liraglutide in participants with knee osteoarthritis: secondary analyses of a randomised trial","volume":"29","author":"Bartholdy","year":"2021","journal-title":"Osteoarthritis and Cartilage"},{"issue":"2","key":"10.1002\/14651858.CD016017-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"100255","DOI":"10.1016\/j.ocarto.2022.100255","article-title":"Changes in physical activity during a one-year weight loss trial with liraglutide vs placebo in participants with knee osteoarthritis: secondary analyses of a randomised controlled trial","volume":"4","author":"Bartholdy","year":"2022","journal-title":"Osteoarthritis and Cartilage Open"},{"key":"10.1002\/14651858.CD016017-BIB0095|cit95","unstructured":"Liraglutide for obese patients with knee osteoarthritis https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=EUCTR2015-005163-16-DK 2016"},{"key":"10.1002\/14651858.CD016017-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"71-2","DOI":"10.1136\/annrheumdis-2019-eular.1375","article-title":"Effect of liraglutide on body weight and pain in the treatment of overweight and knee osteoarthritis: a randomised, double-blind, placebo-controlled study","volume":"78 Suppl 2","author":"Gudbergsen","year":"2019","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD016017-BIB0097|cit97","unstructured":"Ultrasound of the knee in obese patients with knee osteoarthritis; weight maintenance (US-LOSEIT-II) https:\/\/clinicaltrials.gov\/study\/NCT02931383"},{"key":"10.1002\/14651858.CD016017-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"107-8","DOI":"10.1136\/annrheumdis-2020-eular.3088","article-title":"Effect of weight loss and liraglutide on serum urate levels among obese knee osteoarthritis patients: secondary analysis of a randomised controlled trial","volume":"79 Suppl 1","author":"Zobbe","year":"2020","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD016017-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/JCP.0000000000001803","article-title":"Liraglutide in obese or overweight individuals with stable bipolar disorder","volume":"44","author":"McElroy","year":"2024","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD016017-BIB0100|cit100","unstructured":"Saxenda in obese or overweight patients with stable bipolar disorder (investigator initiated) https:\/\/clinicaltrials.gov\/study\/NCT03158805"},{"issue":"1","key":"10.1002\/14651858.CD016017-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/oby.22359","article-title":"Intensive behavioral therapy for obesity combined with liraglutide 3.0 mg: a randomized controlled trial","volume":"27","author":"Wadden","year":"2019","journal-title":"Obesity"},{"issue":"12","key":"10.1002\/14651858.CD016017-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1002\/oby.22653","article-title":"Effects of liraglutide and behavioral weight loss on food cravings, eating behaviors, and eating disorder psychopathology","volume":"27","author":"Chao","year":"2019","journal-title":"Obesity"},{"issue":"6","key":"10.1002\/14651858.CD016017-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"e12340","DOI":"10.1111\/cob.12340","article-title":"Changes in health-related quality of life with intensive behavioural therapy combined with liraglutide 3.0 mg per day","volume":"9","author":"Chao","year":"2019","journal-title":"Clinical Obesity"},{"key":"10.1002\/14651858.CD016017-BIB0104|cit104","unstructured":"Lifestyle modification and liraglutide (MODEL) https:\/\/clinicaltrials.gov\/study\/NCT02911818"},{"key":"10.1002\/14651858.CD016017-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"103639","DOI":"10.1016\/j.brat.2020.103639","article-title":"Measures of adherence as predictors of early and total weight loss with intensive behavioral therapy for obesity combined with liraglutide 3.0 mg","volume":"131","author":"Tronieri","year":"2020","journal-title":"Behaviour Research and Therapy"},{"issue":"2","key":"10.1002\/14651858.CD016017-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41366-019-0348-6","article-title":"Effects of liraglutide on appetite, food preoccupation, and food liking: results of a randomized controlled trial","volume":"44","author":"Tronieri","year":"2020","journal-title":"International Journal of Obesity"},{"key":"10.1002\/14651858.CD016017-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.metabol.2019.03.005","article-title":"Effects of liraglutide plus phentermine in adults with obesity following 1year of treatment by liraglutide alone: a randomized placebo-controlled pilot trial","volume":"96","author":"Tronieri","year":"2019","journal-title":"Metabolism: Clinical and Experimental"},{"issue":"6","key":"10.1002\/14651858.CD016017-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2337\/dc20-2151","article-title":"Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study","volume":"44","author":"Nahra","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD016017-BIB0109|cit109","unstructured":"A study to evaluate the efficacy and safety of MEDI0382 in the treatment of overweight and obese subjects with type 2 diabetes https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-000626-35\/HU 2017"},{"key":"10.1002\/14651858.CD016017-BIB0110|cit110","doi-asserted-by":"publisher","first-page":"S54-S55","DOI":"10.1016\/S0168-8278(20)30655-3","article-title":"Effects of cotadutide on biomarkers of non-alcoholic steatohepatitis in overweight or obese subjects with type 2 diabetes mellitus: a 54-week analysis of a randomized phase 2b study","volume":"73","author":"Nahra","year":"2020","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD016017-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"1354A-1355A","DOI":"10.1002\/hep.30941","article-title":"Holistic effects of cotadutide (MEDI0382) on metabolic, cardiovascular, and hepatic parameters in overweight or obese subjects with type 2 diabetes mellitus (T2DM): a 26-week analysis of a randomized phase 2b study","volume":"70","author":"Nahra","year":"2019","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD016017-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"24A-25A","DOI":"10.1002\/hep.30940","article-title":"Effects of cotadutide (MEDI0382) on biomarkers of nonalcoholic steatohepatitis (NASH) in overweight or obese subjects with type 2 diabetes mellitus (T2DM): a 26-week analysis of a randomized phase 2b study","volume":"70","author":"Nahra","year":"2019","journal-title":"Hepatology"},{"issue":"9","key":"10.1002\/14651858.CD016017-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S2213-8587(21)00179-0","article-title":"Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial","volume":"9","author":"Neeland","year":"2021","journal-title":"Lancet Diabetes Endocrinology"},{"issue":"3","key":"10.1002\/14651858.CD016017-BIB0114|cit114","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/jcsm.13445","article-title":"Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: results from a randomized clinical trial","volume":"15","author":"Pandey","year":"2024","journal-title":"Journal of Cachexia, Sarcopenia and Muscle"},{"key":"10.1002\/14651858.CD016017-BIB0115|cit115","unstructured":"Impact of liraglutide 3.0 on body fat distribution https:\/\/clinicaltrials.gov\/study\/NCT03038620"},{"key":"10.1002\/14651858.CD016017-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"221\u2013LB","DOI":"10.2337\/db21-221-LB","article-title":"Effects of liraglutide on visceral and ectopic fat in adults with overweight\/obesity at high cardiovascular risk: a randomized clinical trial","volume":"70 Suppl 1","author":"Neeland","year":"2021","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD016017-BIB0117|cit117","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1007\/s00125-022-05755-w","article-title":"Effect of liraglutide on muscle fat infiltration in adults with overweight or obesity: a randomised clinical trial","volume":"65 Supp 1","author":"Patel","year":"2022","journal-title":"Diabetologia"},{"issue":"3","key":"10.1002\/14651858.CD016017-BIB0118|cit118","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1513\/AnnalsATS.202309-821OC","article-title":"Continuous positive airway pressure but not GLP1-mediated weight loss improves early cardiovascular disease in obstructive sleep apnea: a randomized proof-of-concept study","volume":"21","author":"O'Donnell","year":"2024","journal-title":"Annals of the American Thoracic Society"},{"key":"10.1002\/14651858.CD016017-BIB0119|cit119","unstructured":"O'Donnell C Crilly S O'Mahony A O'Riordan B Traynor M Gitau R Continuous positive airway pressure but not liraglutide-mediated weight loss improves early cardiovascular disease in obstructive sleep apnea: data from a randomized proof-of-concept study MedRxiv 10.1101\/2023.05.23.23290424"},{"key":"10.1002\/14651858.CD016017-BIB0120|cit120","unstructured":"Effect of liraglutide vs CPAP on cardiometabolic outcomes in obstructive sleep apnea https:\/\/clinicaltrials.gov\/study\/NCT04186494"},{"key":"10.1002\/14651858.CD016017-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"28-9","DOI":"10.1159\/000530456","article-title":"The effect of treatment with a glucagon-like-peptide-1 analogue on metabolic activity in adipose tissue: data from a proof-of-concept PET-CT study","volume":"16 Suppl 1","author":"O'Donnell","year":"2023","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD016017-BIB0122|cit122","doi-asserted-by":"crossref","unstructured":"O'Donnell C Crilly S O'Mahony A Dodd J O'Shea D Murphy D The benefit of a liraglutide-based weight loss regimen alone or in addition to standard CPAP therapy on metabolic function, atherosclerosis and inflammation in patients with obstructive sleep apnoea - an explorative, proof of concept study American Thoracic Society 2022 International Conference 2022 S183-S184 10.1007\/s11845-022-03209-1","DOI":"10.1164\/ajrccm-conference.2022.205.1_MeetingAbstracts.A2335"},{"issue":"10148","key":"10.1002\/14651858.CD016017-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O'Neil","year":"2018","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD016017-BIB0124|cit124","unstructured":"Investigation of safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus https:\/\/clinicaltrials.gov\/study\/NCT02453711 2015"},{"key":"10.1002\/14651858.CD016017-BIB0125|cit125","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1159\/000489691","article-title":"25th European Congress On Obesity. A randomised, phase 2, placebo-and active-controlled dose-ranging study of semaglutide for treatment of obesity in subjects without diabetes","volume":"11 Suppl 1","author":"Wilding","year":"2018","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD016017-BIB0126|cit126","unstructured":"Mosenzon O Wilding J Birkenfeld AL McGowan B Pedersen SD Wharton S HbA1c changes in subjects with obesity without diabetes receiving semaglutide (SEMA) for weight management 25th European Congress on Obesity 2019 249 9 10.1159\/000489691"},{"key":"10.1002\/14651858.CD016017-BIB0127|cit127","unstructured":"Birkenfeld AL Wharton S McGowan B Giwercman CC Heerdegen JC Endahl L Weight loss and nausea in subjects receiving semaglutide for the treatment of obesity 26th European Congress on Obesity 2019 247 7"},{"key":"10.1002\/14651858.CD016017-BIB0128|cit128","unstructured":"Mosenzon O Wilding J Birkenfeld AL McGowan B Pedersen SD Wharton S HbA1c changes in subjects with obesity without diabetes receiving semaglutide for weight management 54th EASD Annual Meeting of the European Association for the Study of Diabetes 2018 S352 S353 10.1007\/s00125-018-4693-0"},{"key":"10.1002\/14651858.CD016017-BIB0129|cit129","unstructured":"A randomised, double-blind, parallel group, placebo-controlled trial comparing semaglutide 2.4 mg with semaglutide placebo both administered s.c. once-weekly in subjects with established CV disease and overweight or obesity https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2018\/10\/016193 2018"},{"key":"10.1002\/14651858.CD016017-BIB0130|cit130","unstructured":"Investigation of safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2014-001540-38\/DE 2014"},{"key":"10.1002\/14651858.CD016017-BIB0131|cit131","unstructured":"Monk-Hansen T Van Gaal L Harrison S Rasmussen S Newsome PN The effect of semaglutide on liver enzymes in subjects with obesity and elevated alanine aminotransferase: data from a randomised phase 2 trial 54th EASD Annual Meeting of the European Association for the Study of Diabetes 2018 S589 S589 10.1007\/s00125-018-4693-0"},{"key":"10.1002\/14651858.CD016017-BIB0132|cit132","unstructured":"Wilding J Birkenfeld AL McGowan B Mosenzon O Pedersen SD Wharton S High number of responders with pharmacotherapy-induced weight loss of at least 15% in a placebo-controlled, dose- ranging study of semaglutide in subjects with obesity 25th European Congress on Obesity 2018 280-1 10.1159\/000489691"},{"key":"10.1002\/14651858.CD016017-BIB0133|cit133","unstructured":"O'Neil PM Birkenfeld AL McGowan B Mosenzon O Pedersen SD Wharton S A randomized, phase II, placebo- and active-controlled dose-ranging study of semaglutide for treatment of obesity in subjects without diabetes ENDO 2018: The Endocrine Society Annual Meeting 2018"},{"key":"10.1002\/14651858.CD016017-BIB0134|cit134","unstructured":"Wilding J Birkenfeld AL McGowan B Mosenzon O Pedersen SD Wharton S A randomised, phase 2, placebo- and active-controlled dose-ranging study of semaglutide for treatment of obesity in subjects without diabetes 54 Th EASD Annual Meeting of the European Association for the Study of Diabetes 2018 S273 S274 10.1007\/s00125-018-4693-0"},{"key":"10.1002\/14651858.CD016017-BIB0135|cit135","unstructured":"Newsome PN Ratziu V Calanna S Hansen M Linder M Francque SM High-sensitivity C-reactive protein reductions in subjects with elevated alanine aminotransferase receiving semaglutide for treatment of obesity AASLD 2018 445A 445A 10.1002\/hep.30257"},{"issue":"2","key":"10.1002\/14651858.CD016017-BIB0136|cit136","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/apt.15316","article-title":"Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and\/or obesity","volume":"50","author":"Newsome","year":"2019","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD016017-BIB0137|cit137","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1159\/000489691","article-title":"Changes in SF-36 scores among subjects receiving semaglutide for treatment of obesity","volume":"12","author":"McGowan","year":"2019","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD016017-BIB0138|cit138","unstructured":"Continuous positive airway pressure with or without liraglutide in obstructive sleep apnoea and type 2 diabetes (ROMANCE) clinicaltrialsregister.eu\/ctr-search\/trial\/2014-000988-41\/GB 2014"},{"key":"10.1002\/14651858.CD016017-BIB0139|cit139","unstructured":"A trial of 26 weeks of subcutaneous liraglutide (a GLP1 receptor agonist), with or without continuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoea (OSA) https:\/\/www.isrctn.com\/ISRCTN16250774 10.1186\/ISRCTN16250774"},{"issue":"7","key":"10.1002\/14651858.CD016017-BIB0140|cit140","doi-asserted-by":"publisher","first-page":"e038856","DOI":"10.1136\/bmjopen-2020-038856","article-title":"Randomised, controlled multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without continuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea-hypnoea index (AHI)","volume":"10","author":"Sprung","year":"2020","journal-title":"BMJ Open"},{"issue":"18","key":"10.1002\/14651858.CD016017-BIB0141|cit141","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","article-title":"Healthy weight loss maintenance with exercise, liraglutide, or both combined","volume":"384","author":"Lundgren","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD016017-BIB0142|cit142","doi-asserted-by":"publisher","first-page":"312-13","DOI":"10.1159\/000538577","article-title":"Exercise reduces chronic low-grade inflammation in adults with obesity after weight loss: a randomized clinical trial","volume":"17","author":"Alkhefagie","year":"2024","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD016017-BIB0143|cit143","doi-asserted-by":"publisher","first-page":"i10","DOI":"10.1093\/humrep\/deac104.017","article-title":"Sperm count is increased by diet-induced weight loss and maintained by exercise or GLP-1 analogue treatment: a randomised controlled trial","volume":"37","author":"Andersen","year":"2022","journal-title":"Human Reproduction"},{"key":"10.1002\/14651858.CD016017-BIB0144|cit144","doi-asserted-by":"publisher","first-page":"559-560","DOI":"10.1159\/000538577","article-title":"Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial","volume":"17","author":"Sandsdal","year":"2024","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD016017-BIB0145|cit145","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1159\/000538577","article-title":"Effect of exercise and GLP-1 receptor agonist treatment on sub-clinical atherosclerosis in adults with obesity: a randomized clinical trial","volume":"17","author":"Sandsdal","year":"2024","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD016017-BIB0146|cit146","doi-asserted-by":"publisher","first-page":"686","DOI":"10.2337\/db20-686-P","article-title":"Exercise alone and in combination with liraglutide exert clinically relevant improvements in cardiorespiratory fitness during 1-year weight loss maintenance: the S-LITE randomized trial","volume":"69","author":"Jensen","year":"2020","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD016017-BIB0147|cit147","doi-asserted-by":"publisher","first-page":"S290","DOI":"10.1007\/s00125-020-05221-5","article-title":"Exercise alone and in combination with liraglutide improves cardiorespiratory fitness and physical functioning during weight loss maintenance","volume":"63 Suppl 1","author":"Jensen","year":"2020","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD016017-BIB0148|cit148","unstructured":"Combined effects of GLP-1 analogue and exercise on maintenance of weight loss and health after very-low calorie diet Clinicaltrials.gov\/Study\/NCT04122716 2018"},{"issue":"7","key":"10.1002\/14651858.CD016017-BIB0149|cit149","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1093\/humrep\/deac096","article-title":"Sperm count is increased by diet-induced weight loss and maintained by exercise or GLP-1 analogue treatment: a randomized controlled trial","volume":"37","author":"Andersen","year":"2022","journal-title":"Human Reproduction"},{"key":"10.1002\/14651858.CD016017-BIB0150|cit150","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.2337\/db20-2028-P","article-title":"Adding exercise to liraglutide treatment in weight loss maintenance abolishes the increase in heart rate seen with liraglutide alone: the s-lite randomized trial","volume":"69","author":"Lundgren","year":"2020","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD016017-BIB0151|cit151","doi-asserted-by":"publisher","first-page":"S457","DOI":"10.1007\/s00125-020-05221-5","article-title":"Weight loss-induced improvements of endothelial function and cardiovascular risk factors are maintained with exercise, liraglutide or the combination","volume":"63 Suppl 1","author":"Lundgren","year":"2020","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD016017-BIB0152|cit152","doi-asserted-by":"publisher","first-page":"S275-S276","DOI":"10.1007\/s00125-023-05969-6","article-title":"Exercise combined with GLP-1 receptor agonist preserves bone mineral density during weight loss maintenance","volume":"66","author":"Sandsdal","year":"2023","journal-title":"Diabetologia"},{"issue":"1","key":"10.1002\/14651858.CD016017-BIB0153|cit153","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12933-023-01765-z","article-title":"Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial","volume":"22","author":"Sandsdal","year":"2023","journal-title":"Cardiovascular Diabetology"},{"issue":"5","key":"10.1002\/14651858.CD016017-BIB0154|cit154","doi-asserted-by":"publisher","first-page":"zsac295","DOI":"10.1093\/sleep\/zsac295","article-title":"Insufficient sleep predicts poor weight loss maintenance after 1 year","volume":"46","author":"Bogh","year":"2023","journal-title":"Sleep"},{"key":"10.1002\/14651858.CD016017-BIB0155|cit155","doi-asserted-by":"publisher","first-page":"S243","DOI":"10.1007\/s00125-023-05969-6","article-title":"Plasma levels of liver-expressed antimicrobial peptide 2 (LEAP2) decrease in response to weight loss and treatment with liraglutide and exercise","volume":"66","author":"Byberg","year":"2023","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD016017-BIB0156|cit156","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/clinem\/dgae775","article-title":"Weight loss induces changes in vitamin D status in women with obesity but not in men: a randomized clinical trial","volume":"dgae775","author":"Holt","year":"2024","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD016017-BIB0157|cit157","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.2337\/db20-1974-P","article-title":"Diet-induced weight loss improves sleep quality and these improvements are sustained with one year of weight maintenance with exercise: the S-LITE randomized trial","volume":"69","author":"Janus","year":"2020","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD016017-BIB0158|cit158","doi-asserted-by":"publisher","first-page":"S259","DOI":"10.1007\/s00125-020-05221-5","article-title":"Diet-induced weight loss improves sleep quality and the improvements are sustained after 1 year weight maintenance with exercise and liraglutide: the S-LITE randomised trial","volume":"63 Suppl 1","author":"Janus","year":"2020","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD016017-BIB0159|cit159","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2337\/db20-139-OR","article-title":"Superior effect of 1-year treatment with GLP-1 receptor agonist and exercise on weight loss maintenance and body composition after a very low-calorie diet: the s-lite randomized trial","volume":"69","author":"Janus","year":"2020","journal-title":"Diabetologia"},{"issue":"101733727","key":"10.1002\/14651858.CD016017-BIB0160|cit160","doi-asserted-by":"publisher","first-page":"102475","DOI":"10.1016\/j.eclinm.2024.102475","article-title":"Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial","volume":"69","author":"Jensen","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1002\/14651858.CD016017-BIB0161|cit161","doi-asserted-by":"publisher","first-page":"4770","DOI":"10.1038\/s41467-022-32307-y","article-title":"Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment","volume":"13","author":"Jensen","year":"2022","journal-title":"Nature Communications"},{"issue":"4","key":"10.1002\/14651858.CD016017-BIB0162|cit162","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/oby.23715","article-title":"Weight loss maintenance with exercise and liraglutide improves glucose tolerance, glucagon response, and beta cell function","volume":"31","author":"Jensen","year":"2023","journal-title":"Obesity"},{"issue":"11","key":"10.1002\/14651858.CD016017-BIB0163|cit163","doi-asserted-by":"publisher","first-page":"e031431","DOI":"10.1136\/bmjopen-2019-031431","article-title":"Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet","volume":"9","author":"Jensen","year":"2019","journal-title":"BMJ Open"},{"issue":"6","key":"10.1002\/14651858.CD016017-BIB0164|cit164","doi-asserted-by":"publisher","first-page":"e2416775","DOI":"10.1001\/jamanetworkopen.2024.16775","article-title":"Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: a secondary analysis of a randomized clinical trial","volume":"7","author":"Jensen","year":"2024","journal-title":"JAMA Network Open"},{"key":"10.1002\/14651858.CD016017-BIB0165|cit165","doi-asserted-by":"publisher","first-page":"S292","DOI":"10.1007\/s00125-020-05221-5","article-title":"Superior effect of 1-year treatment with GLP-1 receptor agonist and exercise on weight loss maintenance and body composition after a very low-calorie diet: the S-LITE trial","volume":"63 Suppl 1","author":"Torekov","year":"2020","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD016017-BIB0166|cit166","unstructured":"The additive effect of the appetite hormone GLP-1 (liraglutide) and exercise on maintenance of weight loss and on health parameters after a low calorie diet https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-005585-32\/DK 2016"},{"issue":"7","key":"10.1002\/14651858.CD016017-BIB0167|cit167","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD016017-BIB0168|cit168","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/dme.17_13048","article-title":"Efficacy and safety of liraglutide 3.0 mg and 1.8 mg in weight loss responders vs nonresponders in overweight\/obese adults with type 2 diabetes: a subgroup analysis of the SCALE diabetes trial","volume":"33 Suppl 1","author":"Davies","year":"2016","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD016017-BIB0169|cit169","doi-asserted-by":"publisher","first-page":"i1\u2013i1599","DOI":"10.1093\/edrv\/36.supp.1","article-title":"Efficacy and safety of liraglutide 3.0 mg and 1.8 mg in weight loss responders from overweight\/obese adults with type 2 diabetes (T2D): a subgroup analysis of the scale diabetes trial","volume":"36 Suppl 1","author":"DeFronzo","year":"2015","journal-title":"Endocrine Reviews"},{"key":"10.1002\/14651858.CD016017-BIB0170|cit170","unstructured":"Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes A 56 week randomised, double-blind, placebocontrolled, three armed parallel group, multi-centre, multinational trial with a 12 week observational follow-up period https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2008-002199-88\/SE 2008"},{"key":"10.1002\/14651858.CD016017-BIB0171|cit171","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/dme.13302","article-title":"The efficacy and safety of liraglutide 3.0mg for weight management are similar across baseline Edmonton Obesity Staging System (EOSS) categories: post-hoc analysis at 56 weeks","volume":"34 Suppl 1","author":"Wilding","year":"2017","journal-title":"Diabetic Medicine"},{"issue":"4","key":"10.1002\/14651858.CD016017-BIB0172|cit172","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/dom.12632","article-title":"Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials","volume":"18","author":"Ard","year":"2016","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1002\/14651858.CD016017-BIB0173|cit173","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/obr.12401","article-title":"Neuropsychiatric safety profile in randomized controlled phase 2 and 3 trials with once-daily subcutaneous liraglutide 3.0 Mg for weight management (WM)","volume":"17 Suppl 2","author":"Aroda","year":"2016","journal-title":"Obesity Reviews"},{"issue":"Suppl. 1","key":"10.1002\/14651858.CD016017-BIB0174|cit174","doi-asserted-by":"publisher","first-page":"A564","DOI":"10.2337\/db1519292253","article-title":"Early response to liraglutide 3.0 mg in adults with overweight or obesity and type 2 diabetes: subanalysis of the SCALE diabetes trial","volume":"64","author":"Davies","year":"2015","journal-title":"Diabetes"},{"issue":"3","key":"10.1002\/14651858.CD016017-BIB0175|cit175","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/dom.13125","article-title":"Liraglutide and cardiovascular outcomes in adults with overweight or obesity: a post hoc analysis from SCALE randomized controlled trials","volume":"20","author":"Davies","year":"2018","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1002\/14651858.CD016017-BIB0176|cit176","doi-asserted-by":"publisher","first-page":"S22-S23","DOI":"10.1007\/s00125-014-3355-0","article-title":"Liraglutide 3.0 mg for weight management in obese\/overweight adults with type 2 diabetes: SCALE diabetes 56-week randomised, double-blind, placebo-controlled trial","volume":"57 Suppl 1","author":"Davies","year":"2014","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD016017-BIB0177|cit177","doi-asserted-by":"publisher","first-page":"i1\u2013i1153","DOI":"10.1093\/edrv\/35.supp.1","article-title":"Effects of liraglutide 3.0 mg and 1.8 mg on body weight and cardiometabolic risk factors in overweight and obese adults with type 2 diabetes mellitus (T2DM): the scale diabetes randomized, double-blind, placebo-controlled, 56-week trial","volume":"35 Suppl 1","author":"DeFronzo","year":"2014","journal-title":"Endocrine Reviews"},{"key":"10.1002\/14651858.CD016017-BIB0178|cit178","doi-asserted-by":"publisher","first-page":"A518-A519","DOI":"10.2337\/db14-1741-2092","article-title":"Effects of liraglutide 3.0 mg cessation on efficacy and safety\/ tolerability following a 56-week randomized treatment period in obese\/overweight adults with type 2 diabetes (Scale\u2122 diabetes)","volume":"63 Suppl 1","author":"Defronzo","year":"2014","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD016017-BIB0179|cit179","doi-asserted-by":"publisher","first-page":"183-4","DOI":"10.1159\/000446744","article-title":"Neuropsychiatric safety profile with liraglutide 3.0 mg for weight management across randomised, placebo-controlled, double-blind phase 2 and 3 trials","volume":"9 Suppl 1","author":"Kushner","year":"2016","journal-title":"Obesity Facts"},{"issue":"6","key":"10.1002\/14651858.CD016017-BIB0180|cit180","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1159\/000478099","article-title":"Comparison of efficacy and safety of liraglutide 3.0 mg in individuals with bmi above and below 35 kg\/m2: a post-hoc analysis","volume":"10","author":"Le Roux","year":"2017","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD016017-BIB0181|cit181","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1159\/000382140","article-title":"Weight loss with liraglutide 3.0 mg is associated with improved health-related quality of life (HRQoL) and treatment satisfaction in overweight or obese adults with type 2 diabetes (T2D)","volume":"8 Suppl 1","author":"Le Roux","year":"2015","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD016017-BIB0182|cit182","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/dme.12668","article-title":"Cessation of liraglutide 3.0mg in obese\/ overweight adults with type 2 diabetes: effects on efficacy and safety of a 12 week off-treatment period after a 56 week randomised treatment period in the SCALE diabetes trial","volume":"32 Suppl 1","author":"Millward","year":"2015","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD016017-BIB0183|cit183","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1159\/000382140","article-title":"Efficacy and safety of liraglutide 3.0 mg and 1.8 mg in weight loss responders vs non-responders in overweight\/obese adults with type 2 diabetes (T2D): a subgroup analysis of the scale diabetes trial","volume":"8 Suppl 1","author":"Mosenzon","year":"2015","journal-title":"Obesity Facts"},{"issue":"11","key":"10.1002\/14651858.CD016017-BIB0184|cit184","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.4158\/EP151181.OR","article-title":"Effects of liraglutide 3.0 mg on weight and risk factors in Hispanic versus non-Hipanic populations: subgroup analysis from SCALE randomized trials","volume":"22","author":"O'Neil","year":"2016","journal-title":"Endocrine Practice"},{"issue":"11","key":"10.1002\/14651858.CD016017-BIB0185|cit185","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s40262-016-0410-7","article-title":"Liraglutide 3.0 mg for weight management: a population pharmacokinetic analysis","volume":"55","author":"Overgaard","year":"2016","journal-title":"Clinical Pharmacokinetics"},{"issue":"6","key":"10.1002\/14651858.CD016017-BIB0186|cit186","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/dom.13985","article-title":"Impact of dose-escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0 mg: a model-based approach","volume":"22","author":"Papathanasiou","year":"2020","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"11","key":"10.1002\/14651858.CD016017-BIB0187|cit187","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000382140","article-title":"Liraglutide 3.0 mg: weight-loss dependent and independent effects","volume":"36","author":"Bays","year":"2015","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD016017-BIB0188|cit188","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/dme.12668","article-title":"Liraglutide 3.0mg results in significant weight loss and improvements in cardiometabolic risk factors compared with liraglutide 1.8mg or placebo: a randomised, double-blind, 56 week trial in overweight\/ obese adults with type 2 diabetes (SCALE diabetes)","volume":"32","author":"Davies","year":"2015","journal-title":"Diabetic Medicine"},{"issue":"11","key":"10.1002\/14651858.CD016017-BIB0189|cit189","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1111\/dom.12963","article-title":"Neuropsychiatric safety with liraglutide 3.0 mg for weight management: results from randomized controlled phase 2 and 3a trials","volume":"19","author":"O'Neil","year":"2017","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD016017-BIB0190|cit190","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/03007995.2016.1251892","article-title":"Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects","volume":"33","author":"Bays","year":"2017","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD016017-BIB0191|cit191","doi-asserted-by":"publisher","first-page":"P206","DOI":"10.1055\/s-0036-1580953","article-title":"Early weight loss with liraglutide 3.0 mg is a good predictor of clinically meaningful weight loss after 56 weeks","volume":"11","author":"Blueher","year":"2016","journal-title":"Diabetologie und Stoffwechsel"},{"issue":"1","key":"10.1002\/14651858.CD016017-BIB0192|cit192","doi-asserted-by":"publisher","first-page":"S310","DOI":"10.1007\/s00125-015-3687-4","article-title":"Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks","volume":"58","author":"Bluher","year":"2015","journal-title":"Diabetologia"},{"issue":"1","key":"10.1002\/14651858.CD016017-BIB0193|cit193","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1007\/s00125-014-3355-0","article-title":"Effect of liraglutide 3.0\/1.8 mg on body weight and cardiometabolic risk factors in overweight\/obese adults with type 2 diabetes: SCALE diabetes randomised, double-blind, 56-week trial","volume":"57","author":"Bode","year":"2014","journal-title":"Diabetologia"},{"issue":"2","key":"10.1002\/14651858.CD016017-BIB0194|cit194","doi-asserted-by":"publisher","first-page":"36","DOI":"10.4081\/itjm.2018.s2","article-title":"Age no impediment to effective weight loss with liraglutide 3.0 mg: data from two randomized trials","volume":"12","author":"Busetto","year":"2018","journal-title":"Italian Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD016017-BIB0195|cit195","doi-asserted-by":"publisher","first-page":"LB7","DOI":"10.1055\/s-0035-1556576","article-title":"Liraglutide 3.0 mg for weight management in obese\/overweight adults with type 2 diabetes: results from the SCALE diabetes 56-week randomized, double-blind, placebo-controlled trial","volume":"10","author":"Davies","year":"2015","journal-title":"Diabetologie und Stoffwechsel"},{"key":"10.1002\/14651858.CD016017-BIB0196|cit196","doi-asserted-by":"publisher","first-page":"A26","DOI":"10.2337\/db14-1-388","article-title":"Liraglutide 3.0 mg for weight management in obese\/overweight adults with type 2 diabetes: results from the Scale\u2122 diabetes 56-week randomized, double-blind, placebo-controlled trial","volume":"63 Suppl 1","author":"Davies","year":"2014","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD016017-BIB0197|cit197","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/dme.13302","article-title":"Effectiveness and safety of liraglutide 3.0 and 1.8mg in weight loss responders among adults with overweight\/obesity with type 2 diabetes: SCALE diabetes trial subgroup analysis","volume":"34 Suppl 1","author":"Davies","year":"2017","journal-title":"Diabetic Medicine"},{"issue":"11","key":"10.1002\/14651858.CD016017-BIB0198|cit198","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1002\/oby.21629","article-title":"Early weight loss with liraglutide 3.0 mg predicts 1-year weight loss and is associated with improvements in clinical markers","volume":"24","author":"Fujioka","year":"2016","journal-title":"Obesity"},{"key":"10.1002\/14651858.CD016017-BIB0199|cit199","doi-asserted-by":"publisher","first-page":"i1\u2013i1699","DOI":"10.1210\/endo-meetings.2016.OABA.7.FRI-602","article-title":"Neuropsychiatric safety profile with liraglutide 3.0 mg for weight management: results across randomized controlled phase 2 and 3 trials of up to 56 weeks duration","volume":"37 Suppl 1","author":"O'Neil","year":"2016","journal-title":"Endocrine Reviews"},{"key":"10.1002\/14651858.CD016017-BIB0200|cit200","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1016\/j.jcjd.2015.01.141","article-title":"Effects of liraglutide 3.0 mg and 1.8 mg on body weight and cardiometabolic risk factors in adults with overweight or obesity and type 2 diabetes (T2D): the SCALE diabetes randomized, double-blind, placebo-controlled, 56-week trial","volume":"39","author":"Pedersen","year":"2015","journal-title":"Canadian Journal of Diabetes"},{"key":"10.1002\/14651858.CD016017-BIB0201|cit201","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/obr.12401","article-title":"The efficacy and safety of liraglutide 3.0 mg for weight management are similar across baseline Edmonton obesity staging system (EOSS) categories: post hoc analysis at 56 weeks","volume":"17 Suppl 2","author":"Sharma","year":"2016","journal-title":"Obesity Reviews"},{"issue":"7","key":"10.1002\/14651858.CD016017-BIB0202|cit202","doi-asserted-by":"publisher","first-page":"839","DOI":"10.2337\/dc16-2684","article-title":"Impact of liraglutide on amylase, lipase, and acute pancreatitis in participants with overweight\/obesity and normoglycemia, prediabetes, or type 2 diabetes: secondary analyses of pooled data from the scale clinical development program","volume":"40","author":"Steinberg","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD016017-BIB0203|cit203","doi-asserted-by":"publisher","first-page":"S311","DOI":"10.1007\/s00125-015-3687-4","article-title":"Liraglutide 3.0mg efficacy and safety by baseline BMI in the SCALE diabetes trial: post-hoc analysis","volume":"58 Suppl 1","author":"Udden","year":"2015","journal-title":"Diabetologia"},{"issue":"7","key":"10.1002\/14651858.CD016017-BIB0204|cit204","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jdiacomp.2017.04.003","article-title":"Effect of weight reductions on estimated kidney function: post-hoc analysis of two randomized trials","volume":"31","author":"Scholten","year":"2017","journal-title":"Journal of Diabetes and Its Complications"},{"key":"10.1002\/14651858.CD016017-BIB0205|cit205","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/j.jcjd.2015.01.140","article-title":"Weight loss with liraglutide 3.0 mg is associated with improved health-related quality of life (HRQoL) and treatment satisfaction in adults with overweight\/obesity and type 2 diabetes (T2D): the SCALE diabetes randomized, double-blind, placebo-controlled","volume":"39","author":"Wharton","year":"2015","journal-title":"Canadian Journal of Diabetes"},{"issue":"5","key":"10.1002\/14651858.CD016017-BIB0206|cit206","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/dom.12639","article-title":"Exposure-response analyses of liraglutide 3.0 mg for weight management","volume":"18","author":"Wilding","year":"2016","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1002\/14651858.CD016017-BIB0207|cit207","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/dme.21_13048","article-title":"Early weight loss with liraglutide 3.0 mg is a good predictor of clinically meaningful weight loss after 56 weeks","volume":"33 Suppl 1","author":"Wilding","year":"2016","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD016017-BIB0208|cit208","unstructured":"Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - diabetes https:\/\/clinicaltrials.gov\/study\/NCT01272232 1 1"},{"issue":"3","key":"10.1002\/14651858.CD016017-BIB0209|cit209","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/oby.22726","article-title":"Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial","volume":"28","author":"Wadden","year":"2020","journal-title":"Obesity"},{"key":"10.1002\/14651858.CD016017-BIB0210|cit210","unstructured":"Effect and safety of liraglutide 3.0 mg as an adjunct to intensive behaviour therapy for obesity in a non-specialist setting Clinicaltrials.gov\/Study\/NCT02963935. 2016"},{"key":"10.1002\/14651858.CD016017-BIB0211|cit211","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1159\/000489691","article-title":"P02-192 Effect of weight loss on physical function measured by the 6-minute walking distance test in individuals with obesity: results from the scale ibt trial of liraglutide 3.0 mg","volume":"3 Suppl 1","author":"Rubino","year":"2019","journal-title":"Journal of the Endocrine Society"},{"key":"10.1002\/14651858.CD016017-BIB0212|cit212","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1210\/js.2019-MON-120","article-title":"MON-120 Effect of weight loss on physical function measured by the 6-minute walking distance test in individuals with obesity: results from the SCALE IBT trial of liraglutide 3.0 mg","volume":"12","author":"Rubino","year":"2019","journal-title":"Journal of the Endocrine Society"},{"key":"10.1002\/14651858.CD016017-BIB0213|cit213","doi-asserted-by":"publisher","first-page":"254-5","DOI":"10.1159\/000489691","article-title":"Weight loss with liraglutide 3.0 mg versus placebo for individuals who adhere to the trial drug: a secondary analysis from SCALE IBT","volume":"12","author":"Shaw Tronieri","year":"2019","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD016017-BIB0214|cit214","doi-asserted-by":"publisher","first-page":"43-4","DOI":"10.1159\/000489691","article-title":"Liraglutide 3.0 mg as an adjunct to intensive behaviour therapy in individuals with obesity: SCALE IBT 56-week randomised, double-blind, placebo-controlled trial","volume":"12","author":"Wadden","year":"2019","journal-title":"Obesity Facts"},{"issue":"6","key":"10.1002\/14651858.CD016017-BIB0215|cit215","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1159\/000511130","article-title":"Effects of dietary self-monitoring, physical activity, liraglutide 3.0 mg, and placebo on weight loss in the SCALE IBT trial","volume":"13","author":"Tronieri Jena","year":"2020","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD016017-BIB0216|cit216","doi-asserted-by":"publisher","first-page":"SAT","DOI":"10.1210\/js.2019-SAT-097","article-title":"Weight loss with liraglutide 3.0 mg versus placebo for individuals who adhere to the trial drug: a secondary analysis from SCALE IBT","volume":"13","author":"Tronieri","year":"2019","journal-title":"Journal of the Endocrine Society"},{"key":"10.1002\/14651858.CD016017-BIB0217|cit217","doi-asserted-by":"publisher","first-page":"SAT","DOI":"10.1210\/js.2019-SAT-105","article-title":"Weight loss as determined by adherence to reduced caloric diet, increased physical activity, liraglutide 3.0 mg and placebo: a sub-analysis of the SCALE IBT trial","volume":"3 Suppl 1","author":"Tronieri","year":"2019","journal-title":"Journal of the Endocrine Society"},{"key":"10.1002\/14651858.CD016017-BIB0218|cit218","doi-asserted-by":"publisher","first-page":"SAT","DOI":"10.1210\/js.2019-SAT-099","article-title":"Liraglutide 3.0 mg as an adjunct to intensive behavior therapy in individuals with obesity: SCALE IBT 56-week randomized, double-blind, placebo-controlled trial","volume":"13","author":"Wadden","year":"2019","journal-title":"Journal of Endocrine Society"},{"key":"10.1002\/14651858.CD016017-BIB0219|cit219","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1159\/000489691","article-title":"Outcomes in early responders achieving \u22655% weight loss at 16 weeks with liraglutide 3.0 mg as an adjunct to intensive behaviour therapy (IBT) in individuals with obesity in the SCALE IBT trial","volume":"12","author":"Wadden","year":"2019","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD016017-BIB0220|cit220","unstructured":"Birkenfeld AL Dicker D Garvey T Mingrone G Pedersen SD Satylganova A Outcomes in early responders achieving \u22655% weight loss at16 weeks with treatment with liraglutide 3.0 mg in peoplewith overweight or obesity and basal insulin-treated type 2diabetes (T2D) in the SCALE Insulin trial Obesity Facts 2019 246 7 10.1159\/000489691"},{"issue":"5","key":"10.1002\/14651858.CD016017-BIB0221|cit221","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.2337\/dc19-1745","article-title":"Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE insulin randomized controlled trial","volume":"43","author":"Garvey","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD016017-BIB0222|cit222","doi-asserted-by":"publisher","first-page":"S278","DOI":"10.1007\/s00125-019-4946-6","article-title":"Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE Insulin trial","volume":"62","author":"Mingrone","year":"2019","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD016017-BIB0223|cit223","doi-asserted-by":"publisher","first-page":"13-14","DOI":"10.1159\/000489691","article-title":"Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes (T2D) treated with basal insulin: the SCALE Insulin Trial","volume":"12","author":"Garvey","year":"2019","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD016017-BIB0224|cit224","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1159\/000489691","article-title":"Effect of liraglutide 3.0 mg on glycaemic control parameters in individuals with overweight\/obesity and type 2 diabetes (2D) treated with basal insulin: results from the SCALE Insulin trial","volume":"12","author":"Dicker","year":"2019","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD016017-BIB0225|cit225","unstructured":"Effect and safety of liraglutide 3.0 mg in subjects with overweight or obesity and type 2 diabetes mellitus treated with basal insulin https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-005619-33\/DE 2016"},{"key":"10.1002\/14651858.CD016017-BIB0226|cit226","doi-asserted-by":"publisher","first-page":"246-7","DOI":"10.1159\/000489691","article-title":"Outcomes in early responders achieving \u22655% weight loss at 16 weeks with treatment with liraglutide 3.0 mg in people with overweight or obesity and basal insulin-treated type 2 diabetes (T2D) in the SCALE Insulin trial","volume":"12","author":"Birkenfeld","year":"2019","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD016017-BIB0227|cit227","unstructured":"Effect and safety of liraglutide 3.0 mg in subjects with overweight or obesity and type 2 diabetes mellitus treated with basal insulin https:\/\/clinicaltrials.gov\/study\/NCT02963922"},{"issue":"11","key":"10.1002\/14651858.CD016017-BIB0228|cit228","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study","volume":"37","author":"Wadden","year":"2013","journal-title":"International Journal of Obesity"},{"issue":"1","key":"10.1002\/14651858.CD016017-BIB0229|cit229","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/ijo.2014.88","article-title":"Erratum: weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study","volume":"39","author":"Wadden","year":"2015","journal-title":"International Journal of Obesity"},{"key":"10.1002\/14651858.CD016017-BIB0230|cit230","doi-asserted-by":"publisher","first-page":"S177","DOI":"10.1038\/oby.2011.225","article-title":"Liraglutide improves weight maintenance and weight loss in obese adults without diabetes after diet-induced weight loss: the SCALE\u2122 56-week randomized study","volume":"19","author":"Aronne","year":"2011","journal-title":"Obesity"},{"key":"10.1002\/14651858.CD016017-BIB0231|cit231","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/dme.30_13571","article-title":"Early responders to liraglutide 3.0mg as adjunct to diet and exercise from the SCALE","volume":"35 Suppl 1","author":"Le Roux","year":"2018","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD016017-BIB0232|cit232","unstructured":"Comparison of liraglutide versus placebo in weight loss maintenance in obese subjects: SCALE - maintenance https:\/\/clinicaltrials.gov\/study\/NCT00781937"},{"key":"10.1002\/14651858.CD016017-BIB0233|cit233","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s40519-018-0576-0","article-title":"Early responders to liraglutide 3.0 mg as adjunct to diet and exercise from the scale maintenance trial","volume":"23","author":"Muratori","year":"2018","journal-title":"Eating and Weight Disorders"},{"key":"10.1002\/14651858.CD016017-BIB0234|cit234","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/1753-0407.12032","article-title":"Diet-induced weight loss and subsequent addition of liraglutide 3.0 mg reduces impaired fasting glucose in overweight\/obese adults in the SCALE maintenance 56-week randomised trial","volume":"5","author":"Hollander","year":"2013","journal-title":"Journal of Diabetes"},{"key":"10.1002\/14651858.CD016017-BIB0235|cit235","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1159\/000207438","article-title":"Effect of diet-induced weight loss and subsequent addition of liraglutide 3.0 MG on impaired fasting glucose in overweight\/obese adults in the SCALE maintenance 56-week phase 3 randomised trial","volume":"5","author":"Klein","year":"2012","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD016017-BIB0236|cit236","doi-asserted-by":"publisher","first-page":"S177","DOI":"10.1038\/oby.2011.225","article-title":"Effect of liraglutide on cardiovascular (CV) risk factors in adults without diabetes after diet-induced weight loss: the SCALE\u2122 56-week randomized study","volume":"19","author":"Klein","year":"2011","journal-title":"Obesity"},{"key":"10.1002\/14651858.CD016017-BIB0237|cit237","doi-asserted-by":"publisher","first-page":"A502","DOI":"10.2337\/db11-1625-1928","article-title":"Liraglutide provides weight maintenance and additional weight loss after low calorie diet-induced weight loss in obese subjects without diabetes: the SCALE\u2122 maintenance study","volume":"60 Suppl 1","author":"Wadden","year":"2011","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD016017-BIB0238|cit238","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1007\/s00125-011-2276-4","article-title":"Liraglutide promotes weight maintenance and additional weight loss in obese adults without diabetes after diet-induced weight loss: the SCALE\u2122 56-week randomised study","volume":"54","author":"Woo","year":"2011","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD016017-BIB0239|cit239","doi-asserted-by":"publisher","first-page":"37-38","DOI":"10.1159\/000468958","article-title":"Early responders to liraglutide 3.0 mg as adjunct to diet and exercise from the scale maintenance trial","volume":"10","author":"Wharton","year":"2017","journal-title":"Obesity Facts"},{"issue":"1","key":"10.1002\/14651858.CD016017-BIB0240|cit240","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD016017-BIB0241|cit241","doi-asserted-by":"publisher","first-page":"P102","DOI":"10.1055\/s-0036-1580948","article-title":"Effects of treatment with liraglutide 3.0 mg in subjects with BMI < 35 and BMI \u226535 kg\/m2: subgroup analysis of the SCALE Obesity and Prediabetes 56-week trial","volume":"11","author":"Aberle","year":"2016","journal-title":"Diabetologie und Stoffwechsel"},{"key":"10.1002\/14651858.CD016017-BIB0242|cit242","doi-asserted-by":"publisher","first-page":"A510","DOI":"10.2337\/db16-1771-2041","article-title":"Characteristics of individuals developing type 2 diabetes in the scale obesity and prediabetes randomized, double-blind, liraglutide vs. placebo trial","volume":"65 Suppl 1","author":"Lau","year":"2016","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD016017-BIB0243|cit243","doi-asserted-by":"publisher","first-page":"68-9","DOI":"10.1111\/obr.12401","article-title":"Early weight loss responders to liraglutide 3.0 mg had greater weight loss, regression to normoglycaemia, and reduced T2D development at 3 years vs early non-responders: SCALE obesity and prediabetes","volume":"17 Suppl 2","author":"Lau","year":"2016","journal-title":"Obesity Reviews"},{"key":"10.1002\/14651858.CD016017-BIB0244|cit244","first-page":"S48-49","article-title":"Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight\/obesity: the SCALE obesity and prediabetes randomised trial","volume":"39 Suppl 1","author":"Lau","year":"2015","journal-title":"Canadian Journal of Diabetes"},{"key":"10.1002\/14651858.CD016017-BIB0245|cit245","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1159\/000446744","article-title":"Early weight loss responders to liraglutide 3.0 mg achieved greater weight loss and regression to normoglycaemia, and reduced development of T2D at 3 years, versus early nonresponders in the SCALE Obesity and Prediabetes trial","volume":"9","author":"Madsbad","year":"2016","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD016017-BIB0246|cit246","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0036-1580798","article-title":"Reduction in the risk of developing type 2 diabetes (T2D) with liraglutide 3.0 mg in people with prediabetes from the SCALE Obesity and Prediabetes randomized, double-blind, placebo-controlled trial","volume":"11","author":"Kern","year":"2016","journal-title":"Diabetologie und Stoffwechsel"},{"key":"10.1002\/14651858.CD016017-BIB0247|cit247","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000363668","article-title":"Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, doubleblind and placebo-controlled trial","volume":"7","author":"Wilding","year":"2014","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD016017-BIB0248|cit248","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/dme.12668","article-title":"Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre-diabetes trial","volume":"32","author":"Wilding","year":"2015","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD016017-BIB0249|cit249","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/obr.12401","article-title":"Weight loss and improvements in cardiometabolic risk factors with liraglutide 3.0 mg: the SCALE obesity and prediabetes randomized, double-blind, placebo-controlled 3-year trial","volume":"17 Suppl 2","author":"Astrup","year":"2016","journal-title":"Obesity Reviews"},{"key":"10.1002\/14651858.CD016017-BIB0250|cit250","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1159\/000446744","article-title":"Liraglutide 3.0 mg in obese\/overweight adults with or without prediabetes with baseline BMI <35 vs >35 kg\/m2 in the SCALE Obesity and Prediabetes 56-week randomised, double-blind, placebo-controlled trial","volume":"9 Suppl 1","author":"Wilding","year":"2016","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD016017-BIB0251|cit251","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/dme.12668","article-title":"In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of Type 2 diabetes: SCALE obesity and pre-diabetes trial","volume":"32","author":"Wilding","year":"2015","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD016017-BIB0252|cit252","article-title":"Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double-blind, placebo-controlled 56-week scale obesity and prediabetes trial","volume":"36 Suppl 2","author":"Lau","year":"2015","journal-title":"Endocrine Reviews"},{"key":"10.1002\/14651858.CD016017-BIB0253|cit253","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000382140","article-title":"Efficacy and safety of liraglutide 3.0 mg in adult overweight and obese weight loss responders without diabetes: results of the 56-week randomised, controlled, scale obesity and prediabetes trial","volume":"8","author":"Astrup","year":"2015","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD016017-BIB0254|cit254","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1159\/000446744","article-title":"Weight loss and associated improvements in cardiometabolic risk factors with liraglutide 3.0 mg in the SCALE Obesity and Prediabetes randomised, double-blind, placebo-controlled 3-year trial","volume":"9","author":"Astrup","year":"2016","journal-title":"Obesity Facts"},{"issue":"2","key":"10.1002\/14651858.CD016017-BIB0255|cit255","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1210\/endo-meetings.2016.CE.1.OR36-1","article-title":"Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with obesity or overweight and prediabetes: the scale obesity and prediabetes randomized, double-blind, placebo-controlled 3-year trial","volume":"37","author":"Fujioka","year":"2016","journal-title":"Endocrine Reviews"},{"key":"10.1002\/14651858.CD016017-BIB0256|cit256","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000382140","article-title":"Liraglutide 3.0 mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: scale obesity and prediabetes randomized, double-blind, placebo controlled, 56-week trial","volume":"8","author":"Lau","year":"2015","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD016017-BIB0257|cit257","first-page":"S48","article-title":"Additional analyses of the weight-lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial","volume":"39 Suppl 1","author":"Lau","year":"2015","journal-title":"Canadian Journal of Diabetes"},{"key":"10.1002\/14651858.CD016017-BIB0258|cit258","first-page":"S358","article-title":"Liraglutide 3.0 mg improves insulin secretion and action in overweight\/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial","volume":"57","author":"Lau","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD016017-BIB0259|cit259","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/obr.12401","article-title":"Reduced risk of developing type 2 diabetes (T2D) with liraglutide 3.0 mg for weight management: results from the SCALE obesity and prediabetes randomized, double-blind, placebo-controlled 3-year trial","volume":"17 Suppl 2","author":"Le Roux","year":"2016","journal-title":"Obesity Reviews"},{"key":"10.1002\/14651858.CD016017-BIB0260|cit260","first-page":"1","article-title":"Liraglutide 3.0 mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the scale obesity and prediabetes randomized, double-blind, placebo-controlled 56-week trial","volume":"35","author":"Le Roux","year":"2014","journal-title":"Endocrine Reviews"},{"issue":"1","key":"10.1002\/14651858.CD016017-BIB0261|cit261","doi-asserted-by":"publisher","first-page":"S338","DOI":"10.1007\/s00125-014-3355-0","article-title":"Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial","volume":"57","author":"Le Roux","year":"2014","journal-title":"Diabetologia"},{"issue":"1","key":"10.1002\/14651858.CD016017-BIB0262|cit262","doi-asserted-by":"publisher","first-page":"S311","DOI":"10.1007\/s00125-015-3687-4","article-title":"The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme","volume":"58","author":"Le Roux","year":"2015","journal-title":"Diabetologia"},{"issue":"10077","key":"10.1002\/14651858.CD016017-BIB0263|cit263","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial","volume":"389","author":"Le Roux","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD016017-BIB0264|cit264","doi-asserted-by":"publisher","first-page":"S329","DOI":"10.1007\/s00125-016-4046-9","article-title":"Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors: SCALE obesity and prediabetes randomised, double-blind, placebo-controlled 3-year trial","volume":"59","author":"Le Roux","year":"2016","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD016017-BIB0265|cit265","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/dme.13302","article-title":"Early weight loss responders to liraglutide 3.0mg had greater weight loss, regression to normoglycaemia, and reduced Type 2 diabetes development at three years vs early non-responders: SCALE Obesity and Prediabetes","volume":"34","author":"Le Roux","year":"2017","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD016017-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.jcjd.2015.01.142","article-title":"Liraglutide 3.0 mg reduces body weight and improves health-related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double-blind, placebo-controlled, 56-week trial","volume":"39","author":"Liutkus","year":"2015","journal-title":"Canadian Journal of Diabetes"},{"issue":"1","key":"10.1002\/14651858.CD016017-BIB0267|cit267","doi-asserted-by":"publisher","first-page":"S40-S41","DOI":"10.1007\/s00125-016-4046-9","article-title":"Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial","volume":"59","author":"Madsbad","year":"2016","journal-title":"Diabetologia"},{"issue":"1","key":"10.1002\/14651858.CD016017-BIB0268|cit268","doi-asserted-by":"publisher","first-page":"S330","DOI":"10.1007\/s00125-016-4046-9","article-title":"Greater weight loss and regression to normoglycaemia, and reduced risk of T2D, at 3 years in early weight loss responders to liraglutide 3.0 mg vs early non-responders","volume":"59","author":"Wilding","year":"2016","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD016017-BIB0269|cit269","doi-asserted-by":"publisher","first-page":"A568","DOI":"10.2337\/db1519292253","article-title":"Early weight loss responders to liraglutide 3.0 mg in the SCALE obesity and prediabetes trial achieve greater reversal of prediabetes than placebo","volume":"64","author":"Wilding","year":"2015","journal-title":"Diabetes"},{"issue":"4","key":"10.1002\/14651858.CD016017-BIB0270|cit270","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1556575","article-title":"Additional analyses of the weight-lowering efficacy of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomized trial","volume":"10","author":"Greenway","year":"2015","journal-title":"Diabetologie und Stoffwechsel"},{"key":"10.1002\/14651858.CD016017-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.orcp.2014.10.211","article-title":"Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE Obesity and Prediabetes randomised, double-blind, placebo-controlled 56-week trial","volume":"8","author":"Wittert","year":"2014","journal-title":"Obesity Research & Clinical Practice"},{"key":"10.1002\/14651858.CD016017-BIB0272|cit272","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/dme.17_13048","article-title":"Efficacy and safety of liraglutide 3.0 mg in adult overweight and obese weight loss responders without diabetes: results of the randomised, double-blind, placebocontrolled 56 week SCALE Obesity and Prediabetes trial","volume":"33 Suppl 1","author":"Bain","year":"2016","journal-title":"Diabetic Medicine"},{"issue":"1","key":"10.1002\/14651858.CD016017-BIB0273|cit273","doi-asserted-by":"publisher","first-page":"S330","DOI":"10.1007\/s00125-016-4046-9","article-title":"The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF-36: 3-year data","volume":"59","author":"Bjorner","year":"2016","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD016017-BIB0274|cit274","doi-asserted-by":"publisher","first-page":"A565-A566","DOI":"10.2337\/db1519292253","article-title":"Liraglutide 3.0 mg improves health utilities in weight management compared with placebo","volume":"64","author":"Bjorner","year":"2015","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD016017-BIB0275|cit275","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1055\/s-0037-1601675","article-title":"3-year efficacy and safety for liraglutide 3.0 mg in adults with obesity\/overweight, prediabetes and baseline BMI < 35 vs. \u226535 kg\/m2 in the SCALE Obesity and Prediabetes, double-blind, placebo-controlled trial","volume":"12","author":"Bluher","year":"2017","journal-title":"Diabetologie und Stoffwechsel"},{"issue":"1","key":"10.1002\/14651858.CD016017-BIB0276|cit276","doi-asserted-by":"publisher","first-page":"S331","DOI":"10.1007\/s00125-016-4046-9","article-title":"Improvements in 'Impact of Weight on Quality of Life-Lite' score with liraglutide 3.0 mg vs placebo for weight management: 3-year data","volume":"59","author":"Kolotkin","year":"2016","journal-title":"Diabetologia"},{"issue":"4","key":"10.1002\/14651858.CD016017-BIB0277|cit277","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/cob.12146","article-title":"Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management","volume":"6","author":"Kolotkin","year":"2016","journal-title":"Clinical Obesity"},{"issue":"1","key":"10.1002\/14651858.CD016017-BIB0278|cit278","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cob.12226","article-title":"Improvements in health-related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity","volume":"8","author":"Kolotkin","year":"2018","journal-title":"Clinical Obesity"},{"issue":"3","key":"10.1002\/14651858.CD016017-BIB0279|cit279","first-page":"A251-A252","article-title":"Improvement in IWQoL-Lite-derived health utility score with liraglutide 3.0 mg versus placebo over 3 years in prediabetes","volume":"19","author":"Kolotkin","year":"2016","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD016017-BIB0280|cit280","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1159\/000382140","article-title":"Additional analyses of the weight-lowering efficacy of liraglutide 3.0 mg in overweight and obese adults: the scale obesity and prediabetes randomised trial","volume":"8","author":"Krempf","year":"2015","journal-title":"Obesity Facts"},{"issue":"1","key":"10.1002\/14651858.CD016017-BIB0281|cit281","doi-asserted-by":"publisher","first-page":"S368","DOI":"10.1007\/s00125-014-3355-0","article-title":"Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight\/obese adults: the SCALE obesity and prediabetes randomised trial","volume":"57","author":"Krempf","year":"2014","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD016017-BIB0282|cit282","first-page":"1","article-title":"Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the scale obesity and prediabetes randomized, double-blind, placebo-controlled 56-week trial","volume":"35","author":"Lau","year":"2014","journal-title":"Endocrine Reviews"},{"key":"10.1002\/14651858.CD016017-BIB0283|cit283","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/obr.13118","article-title":"Association between body mass index and utility: post hoc analysis of the SCALE Obesity and Prediabetes trial and comparison with data from the Health Survey of England","volume":"21 Suppl 1","author":"Lopes","year":"2020","journal-title":"Obesity Reviews"},{"key":"10.1002\/14651858.CD016017-BIB0284|cit284","unstructured":"Effect of liraglutide on body weight in non-diabetic obese subjects or overweight subjects with co-morbidities: SCALE\u2122 - obesity and pre-diabetes https:\/\/clinicaltrials.gov\/study\/NCT01272219"},{"key":"10.1002\/14651858.CD016017-BIB0285|cit285","unstructured":"Effect of liraglutide on body weight in non-diabetic obese subjects or overweight subjects with co-morbidities: SCALE\u2122 - obesity and pre-diabetes https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2008-001049-24\/DK 2008"},{"issue":"4","key":"10.1002\/14651858.CD016017-BIB0286|cit286","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0035-1556574","article-title":"Efficacy and safety of liraglutide 3.0 mg in adult overweight and obese weight loss responders without diabetes: results of the randomised, double-blind, placebo-controlled 56-week SCALE Obesity and Prediabetes trial","volume":"10","author":"O'Neil","year":"2015","journal-title":"Endocrine Reviews"},{"key":"10.1002\/14651858.CD016017-BIB0287|cit287","article-title":"Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight and obese adults: results from scale obesity and prediabetes, a randomized, double-blind and placebo-controlled 56-week trial","volume":"35","author":"Pi-Sunyer","year":"2014","journal-title":"Endocrine Reviews"},{"issue":"1","key":"10.1002\/14651858.CD016017-BIB0288|cit288","first-page":"S37","article-title":"Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight\/obese adults: the SCALE obesity and prediabetes trial","volume":"57","author":"Pi-Sunyer","year":"2014","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD016017-BIB0289|cit289","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1159\/000446744","article-title":"Liraglutide 3.0 mg reduced the risk of developing type 2 diabetes and decreased body weight in the SCALE Obesity and Prediabetes randomised, double-blind, placebocontrolled trial","volume":"9","author":"Van Gaal","year":"2016","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD016017-BIB0290|cit290","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/obr.12401","article-title":"Effects of treatment with liraglutide 3.0 mg in subjects with BMI <35 and BMI <greater or equal>35kg\/m2: subgroup analysis of the SCALE obesity and prediabetes 56-week trial","volume":"17 Suppl 2","author":"Van Gaal","year":"2016","journal-title":"Obesity Reviews"},{"key":"10.1002\/14651858.CD016017-BIB0291|cit291","doi-asserted-by":"publisher","first-page":"41-2","DOI":"10.1159\/000382140","article-title":"Liraglutide 3.0 mg: weight-loss dependent and independent effects","volume":"8","author":"Van Gaal","year":"2015","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD016017-BIB0292|cit292","article-title":"Liraglutide 3.0 mg improves insulin secretion and action in overweight and obese adults without diabetes: results from scale obesity and prediabetes, a randomized, double-blind and placebo-controlled 56-week trial","volume":"35","author":"Wilding","year":"2014","journal-title":"Endocrine Reviews"},{"issue":"2","key":"10.1002\/14651858.CD016017-BIB0293|cit293","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1210\/endo-meetings.2016.OABA.9.SAT-600","article-title":"Early weight loss responders to liraglutide 3.0 mg achieved greater weight loss and regression to normoglycemia, and reduced development of T2D, at 3 years versus early non-responders in the scale obesity and prediabetes trial","volume":"37","author":"Fujioka","year":"2016","journal-title":"Endocrine Reviews"},{"issue":"1","key":"10.1002\/14651858.CD016017-BIB0294|cit294","doi-asserted-by":"publisher","first-page":"S368-S369","DOI":"10.1007\/s00125-014-3355-0","article-title":"Efficacy and safety of liraglutide 3.0 mg for weight management in overweight\/obese adults: the SCALE obesity and prediabetes trial","volume":"57","author":"Fujioka","year":"2014","journal-title":"Diabetologia"},{"issue":"0","key":"10.1002\/14651858.CD016017-BIB0295|cit295","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.orcp.2014.10.210","article-title":"Efficacy and safety of liraglutide 3.0mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double-blind and placebo-controlled trial","volume":"8","author":"Proietto","year":"2014","journal-title":"Obesity Research & Clinical Practice"},{"issue":"7","key":"10.1002\/14651858.CD016017-BIB0296|cit296","doi-asserted-by":"crossref","first-page":"A674","DOI":"10.1016\/j.jval.2015.09.1991","article-title":"Impact of weight loss on patient-reported outcomes in the scale obesityand prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise(D&E) programme","volume":"18","author":"Kolotkin","year":"2015","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD016017-BIB0297|cit297","first-page":"121","article-title":"Reduction in the risk of developing type 2 diabetes with liraglutide 3.0 mg in people with prediabetes from the SCALE Obesity and Prediabetes randomized, double-blind, placebo-controlled trial","volume":"10","author":"Vettor","year":"2016","journal-title":"Italian Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD016017-BIB0298|cit298","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial","volume":"40","author":"Blackman","year":"2016","journal-title":"International Journal of Obesity"},{"key":"10.1002\/14651858.CD016017-BIB0299|cit299","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1016\/j.sleep.2015.02.058","article-title":"Liraglutide 3.0 mg reduces severity of obstructive sleep apnea and body weight in obese individuals with moderate or severe disease: SCALE sleep apnoea tria","volume":"16 Suppl 1","author":"Blackman","year":"2015","journal-title":"Sleep Medicine"},{"key":"10.1002\/14651858.CD016017-BIB0300|cit300","doi-asserted-by":"publisher","first-page":"31-2","DOI":"10.1159\/000382140","article-title":"Improvements in sleep apnoea endpoints and quality of life are related to the degree of weight loss: results from the randomized, double-blind scale sleep apnoea trial","volume":"8 Suppl 1","author":"Zammit","year":"2015","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD016017-BIB0301|cit301","unstructured":"Effect of liraglutide in obese subjects with moderate or severe obstructive sleep apnoea: SCALE\u2122 - sleep apnoea https:\/\/clinicaltrials.gov\/study\/NCT01557166 2012"},{"key":"10.1002\/14651858.CD016017-BIB0302|cit302","doi-asserted-by":"publisher","first-page":"S125-S126","DOI":"10.1016\/j.sleep.2015.02.1442","article-title":"Improvements in sleep apnea endpoints and quality of life are related to the degree of weight loss: results from the randomized, double-blind scale sleep apnea trial","volume":"16 Suppl 1","author":"Blackman","year":"2015","journal-title":"Sleep Medicine"},{"key":"10.1002\/14651858.CD016017-BIB0303|cit303","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1007\/s00125-014-3355-0","article-title":"Liraglutide 3.0 mg reduces severity of obstructive sleep apnoea and body weight in obese individuals with moderate or severe disease: SCALE sleep apnoea trial","volume":"57 Suppl 1","author":"Blackman","year":"2014","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD016017-BIB0304|cit304","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/j.jcjd.2015.01.139","article-title":"Liraglutide 3.0 mg reduces severity of obstructive sleep apnea and body weight in individuals with obesity and moderate or severe disease: SCALE sleep apnoea trial","volume":"39","author":"Blackman","year":"2015","journal-title":"Canadian Journey of Diabetes"},{"key":"10.1002\/14651858.CD016017-BIB0305|cit305","doi-asserted-by":"publisher","first-page":"A16-A17","DOI":"10.1136\/thoraxjnl-2014-206260.34","article-title":"Liraglutide 3.0 mg reduces severity of obstructive sleep apnoea and body weight in obese individuals with moderate or severe disease: SCALE sleep apnoea trial","volume":"69","author":"Collier","year":"2014","journal-title":"Thorax"},{"issue":"2","key":"10.1002\/14651858.CD016017-BIB0306|cit306","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD016017-BIB0307|cit307","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/oby.23328","article-title":"Semaglutide 2.4 mg vs liraglutide 3.0 mg for weight management in overweight or obesity (STEP 8)","volume":"29 Suppl 2","author":"Rubino","year":"2021","journal-title":"Obesity"},{"key":"10.1002\/14651858.CD016017-BIB0308|cit308","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00125-022-05755-w","article-title":"Semaglutide 2.4 mg improved glucose metabolism and reverted prediabetes to normoglycaemia in adults with overweight or obesity vs liraglutide 3.0 mg (STEP 8)","volume":"65 Suppl 1","author":"Rubino","year":"2022","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD016017-BIB0309|cit309","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1007\/s11695-023-06662-8","article-title":"Semaglutide 2.4 mg improved glucose metabolism and reverted prediabetes to normoglycaemia in adults with overweight or obesity vs liraglutide 3.0 mg (STEP 8)","volume":"33 Suppl 1","author":"Idris","year":"2023","journal-title":"Obesity Surgery"},{"key":"10.1002\/14651858.CD016017-BIB0310|cit310","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.2337\/db22-1413-P","article-title":"Semaglutide 2.4 mg improved glucose metabolism and reverted prediabetes to normoglycemia in adults with overweight\/obesity vs. liraglutide 3.0 mg (STEP 8)","volume":"71 Suppl 1","author":"Rosenstock","year":"2022","journal-title":"Diabetes"},{"issue":"11","key":"10.1002\/14651858.CD016017-BIB0311|cit311","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1111\/dom.14809","article-title":"Ease-of-use and acceptability of the novel semaglutide 2.4 mg single-dose pen-injector in people with overweight or obesity in the STEP 8 phase III trial","volume":"24","author":"Snitker","year":"2022","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1002\/14651858.CD016017-BIB0312|cit312","unstructured":"Research study to investigate how well semaglutide works compared to liraglutide in people living with overweight or obesity https:\/\/ClinicalTrials.gov\/show\/NCT04074161"},{"issue":"101777707","key":"10.1002\/14651858.CD016017-BIB0313|cit313","doi-asserted-by":"publisher","first-page":"100853","DOI":"10.1016\/j.lanepe.2024.100853","article-title":"Effectiveness of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in weight management services (STRIVE study): a multicentre, open-label, parallel-group, randomized controlled trial","volume":"39","author":"Papamargaritis","year":"2024","journal-title":"Lancet Regional Health - Europe"},{"key":"10.1002\/14651858.CD016017-BIB0314|cit314","doi-asserted-by":"publisher","first-page":"e13119","DOI":"10.1111\/obr.13119","article-title":"Can we use calorie intake and food choice measurements to determine individual variation in weight loss success to liraglutide 3.0 mg A direct method of eating behaviour assessment","volume":"21 Suppl 1","author":"Al Najim","year":"2020","journal-title":"Obesity Reviews"},{"issue":"2","key":"10.1002\/14651858.CD016017-BIB0315|cit315","doi-asserted-by":"publisher","first-page":"e034137","DOI":"10.1136\/bmjopen-2019-034137","article-title":"Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial","volume":"10","author":"Papamargaritis","year":"2020","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD016017-BIB0316|cit316","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/oby.23626","article-title":"Effectiveness of a pragmatic pathway for prescribing liraglutide 3mg in obesity services (STRIVE)","volume":"30","author":"Papamargaritis","year":"2022","journal-title":"Obesity"},{"key":"10.1002\/14651858.CD016017-BIB0317|cit317","unstructured":"Saxenda in obesity services (STRIVE study) https:\/\/clinicaltrials.gov\/study\/NCT03036800"},{"issue":"6","key":"10.1002\/14651858.CD016017-BIB0318|cit318","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3892\/etm.2023.11948","article-title":"Effect of liraglutide on atherosclerosis in patients with impaired glucose tolerance: a double-blind, randomized controlled clinical trial","volume":"25","author":"Sun","year":"2023","journal-title":"Experimental and Therapeutic Medicine"},{"key":"10.1002\/14651858.CD016017-BIB0319|cit319","unstructured":"Personalisation of anti-obesity medication selection using the novel Auckland Eating Behaviour Questionnaire to identify Eating Behaviour Traits: examining the impact on weight loss https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ACTRN12622000703707. 2022"},{"key":"10.1002\/14651858.CD016017-BIB0320|cit320","unstructured":"Intervention study of liraglutide in type 2 diabetes mellitus with nonalcoholic fats http:\/\/www.chictr.org.cn\/showproj.aspx?proj=56816. 2020"},{"key":"10.1002\/14651858.CD016017-BIB0321|cit321","unstructured":"Effect of liraglutide combined with metformin on IVF\/ICSI clinical pregnancy rates in obese women with PCOS: study protocol for a prospective, double-blind, single-center randomized controlled trial https:\/\/www.chictr.org.cn\/showproj.html?proj=177212. 2022"},{"key":"10.1002\/14651858.CD016017-BIB0322|cit322","unstructured":"Assessing the efficacy and safety of the GLP1-agonist liraglutide in patients who developed diabetes as a consequence of the use of anti-psychotic drugs https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-005395-18\/NL. 2014"},{"key":"10.1002\/14651858.CD016017-BIB0323|cit323","unstructured":"A pre-pregnancy study examining the effects of an intensive lifestyle package supported with Liraglutide treatment, a medication equivalent to a natural hormone produced in the stomach, in obese women with previous history of pregnancy diabetes https:\/\/www.isrctn.com\/ISRCTN76189107. 2016"},{"key":"10.1002\/14651858.CD016017-BIB0324|cit324","unstructured":"Liraglutide and metformin combination on weight loss, metabolic - endocrine parameters and pregnancy rate in women with PCOS, obesity and infertility https:\/\/clinicaltrials.gov\/study\/NCT05952882. 2023"},{"key":"10.1002\/14651858.CD016017-BIB0325|cit325","unstructured":"Prevention of weight gain when starting insulin therapy in patients with type 2 diabetes https:\/\/onderzoekmetmensen.nl\/en\/trial\/20833. 2011"},{"key":"10.1002\/14651858.CD016017-BIB0326|cit326","unstructured":"Onderzoek naar de effecten van het medicijn liraglutide bij pati\u00ebnten met een type suikerziekte (diabetes) die veroorzaakt is door het gebruik van antipsychotische medicijnen https:\/\/onderzoekmetmensen.nl\/en\/trial\/24018. 2013"},{"key":"10.1002\/14651858.CD016017-BIB0327|cit327","unstructured":"Effects of incretin on the blood pressure and lipid in patients with overweight or obese diabetes https:\/\/clinicaltrials.gov\/study\/NCT02503943"},{"key":"10.1002\/14651858.CD016017-BIB0328|cit328","unstructured":"Efficacy and safety of liraglutide on body weight in obese subjects or overweight subjects with co-morbidities Clinicaltrials.gov\/Study\/NCT04487743."},{"key":"10.1002\/14651858.CD016017-BIB0329|cit329","unstructured":"Gut microbiome changes following liraglutide treatment in obese subjects or overweight subjects with co-morbidities https:\/\/clinicaltrials.gov\/study\/NCT04525300. 2020"},{"key":"10.1002\/14651858.CD016017-BIB0330|cit330","unstructured":"The efficacy and safety of liraglutide on body weight loss in obese and overweight patients https:\/\/clinicaltrials.gov\/study\/NCT04605861. 2020"},{"key":"10.1002\/14651858.CD016017-BIB0331|cit331","unstructured":"Effects of XW003 versus liraglutide on body weight of adult participants with obesity https:\/\/clinicaltrials.gov\/study\/NCT05111912 2021"},{"key":"10.1002\/14651858.CD016017-BIB0332|cit332","unstructured":"Welch VA Petkovic J Jull J Hartling L Klassen T Kristjansson E Chapter 16: Equity and specific populations [last updated October 2019]. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024. Available from https:\/\/www.cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD016017-BIB0333|cit333","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12874-017-0442-1","article-title":"When and how should multiple imputation be used for handling missing data in randomised clinical trials - a practical guide with flowcharts","volume":"17","author":"Jakobsen","year":"2017","journal-title":"BMC Medical Research Methodology"},{"issue":"5","key":"10.1002\/14651858.CD016017-BIB0334|cit334","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/bmjebm-2019-111230","article-title":"What to do with a clinical trial with conflicts of interest","volume":"25","author":"Lundh","year":"2020","journal-title":"BMJ Evidence-Based Medicine"},{"key":"10.1002\/14651858.CD016017-BIB0335|cit335","unstructured":"Boutron I Page MJ Higgins JP Altman DG Lundh A Hr\u00f3bjartsson A Chapter 7: Considering bias and conflicts of interest among the included studies (last updated August 2022). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-07"},{"issue":"79","key":"10.1002\/14651858.CD016017-BIB0336|cit336","doi-asserted-by":"publisher","first-page":"103020","DOI":"10.1016\/j.eclinm.2024.103020","article-title":"Safety and effects of anti-obesity medications on weight loss, cardiometabolic, and psychological outcomes in people living with overweight or obesity: a systematic review and meta-analysis","volume":"1","author":"Liu","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1002\/14651858.CD016017-BIB0337|cit337","doi-asserted-by":"publisher","first-page":"156038","DOI":"10.1016\/j.metabol.2024.156038","article-title":"Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials","volume":"161","author":"Xie","year":"2024","journal-title":"Metabolism: Clinical and Experimental"},{"issue":"10434","key":"10.1002\/14651858.CD016017-BIB0338|cit338","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S0140-6736(24)00351-9","article-title":"Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials","volume":"403","author":"Shi","year":"2024","journal-title":"Lancet"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:18:13Z","timestamp":1790140693000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD016017"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":338,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd016017","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]}}}